BioSpace News Archive

Under the new Provizor brand umbrella, the company will continue to provide diversified health-care services.

Athos Therapeutics, Inc. (the “Company”), a late-stage preclinical biotech company using artificial intelligence to develop small molecule therapeutics for immune-mediated diseases and cancer, announced today that Yiannis Monovoukas , PhD, MBA, and Monte Stettin were appointed as advisors and observers to the Board of Directors.

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today the appointment of leading vaccine experts Dr. Thomas Decker and Dr. Michael Pfleiderer to its Scientific Advisory Board (SAB).

Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients’ lives, announced its participation in the upcoming 2022 American Transplant Congress held on June 4th to June 8th, 2022.

SQZ Biotechnologies, focused on unlocking the full potential of cell therapies for multiple therapeutic areas, announced that it has appointed Marshelle Smith Warren, M.D., as Chief Medical Officer.

AnPac Bio-Medical Science Co., Ltd., a biotechnology company with operations in China and the United States, announced its unaudited financial results for the first quarter ended March 31, 2022.

Ovensa Inc. and Celanese Corporation announced plans to collaborate on the long-acting controlled release of targeted therapeutics that address current performance, toxicity and resistance challenges in the market.

Stryker (NYSE:SYK) today announced that its Q Guidance System received 510(k) clearance from the U.S. Food and Drug Administration.

With Imaging Lab, Median will provide biopharmaceutical companies with new decision-making tools for clinical trials by leveraging images with data mining and Artificial Intelligence (AI) technologies from iBiopsy® and radiomics.

The American Diabetes Association® published important updates to the Standards of Medical Care in Diabetes—2022, in annotations as the Living Standards of Care.